ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Daiichi Sankyo Receives Us Fda Approval For Vanflyta First Flt3 Inhibitor
News Feed
course image
  • Date not available
  • Admin
  • News Article

Daiichi Sankyo Receives US FDA Approval for VANFLYTA® First FLT3 Inhibitor

Daiichi Sankyo announced that VANFLYTA® (quizartinib) has received approval from the U.S. Food and Drug Administration (FDA) for a comprehensive treatment approach in adult patients with newly diagnosed acute myeloid leukaemia (AML) who test positive for FLT3-ITD as determined by an FDA-approved test.

VANFLYTA is the first and only FLT3 inhibitor approved by the FDA for FLT3-ITD positive AML across all three phases of treatment – induction, consolidation, and maintenance – for patients who do not undergo transplant. This means that patients with this specific type of AML can receive VANFLYTA throughout their treatment journey.

VANFLYTA is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML. 

The approval of VANFLYTA represents a significant advancement for the treatment of patients with newly diagnosed FLT3-ITD positive AML, which is one of the most aggressive and difficult-to-treat subtypes.

The approval of VANFLYTA also extends to Japan, where it is approved for the treatment of AML that is FLT3-ITD mutation positive. In Japan, it is approved for use in combination with standard cytarabine and anthracycline induction, standard cytarabine consolidation chemotherapy, and as maintenance monotherapy for adult patients with newly diagnosed FLT3-ITD positive AML. 

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form